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Introduction
Untreated tuberculosis (TB) disease represents 
a greater hazard to a pregnant woman and 
her fetus than does its treatment. Treatment of 
pregnant women should be initiated whenever the 
probability of TB is moderate to high. Infants born 
to women with untreated TB may be of lower birth 
weight than those born to women without TB and, 
in rare circumstances the infant may be born with 
TB. Although the drugs used in the initial treatment 
regimen for TB cross the placenta, they do not 
appear to have harmful effects on the fetus.
Testing
The tuberculin skin test is considered both valid and 
safe to use throughout pregnancy. The TB blood test 
is safe to use during pregnancy, but has not been 
evaluated for diagnosing M. tuberculosis infection in 
pregnant women. Other tests are needed to show if 
a person has TB disease.
Treatment
Latent TB Infection (LTBI) – Isoniazid (INH) 
administered either daily or twice weekly for 9 
months is the standard regimen for the treatment 
of LTBI in pregnant women. Women taking 
INH should also take pyridoxine (vitamin B6) 
supplementation. The 12-dose regimen of INH 
and Rifapentine (RPT) is not recommended for 
pregnant women or women expecting to be 
pregnant within the next 3 months.  
TB Disease - Pregnant women should start 
treatment as soon as TB is suspected. The 
preferred initial treatment regimen is INH, 
rifampin (RIF), and ethambutol (EMB) daily for 2 
months, followed by INH and RIF daily, or twice 
weekly for 7 months (for a total of 9 months of 
treatment). Streptomycin should not be used 
because it has been shown to have harmful 
effects on the fetus. In most cases, pyrazinamide 
(PZA) is not recommended to be used because its 
effect on the fetus is unknown.
HIV Infection - HIV-infected pregnant 
women who are suspected of having TB 
disease should be treated without delay. TB 
treatment regimens for HIV-infected pregnant 
women should include a rifamycin. Although 
the routine use of PZA during pregnancy 
is not recommended in the United States, 
the benefits of a TB treatment regimen that 
includes PZA for HIV-infected pregnant women 
may outweigh the undetermined potential 
risks to the fetus. 
Contraindications
The following antituberculosis drugs are 
contraindicated in pregnant women:
 • Streptomycin 
 • Kanamycin 
 • Amikacin 
 • Capreomycin 
 • Fluoroquinolones 
Women who are being treated for drug-resistant 
TB should receive counseling concerning the risk 
to the fetus because of the known and unknown 
risks of second-line antituberculosis drugs.
Breastfeeding
Breastfeeding should not be discouraged 
for women being treated with the first-
line antituberculosis drugs because the 
concentrations of these drugs in breast milk 
are too small to produce toxicity in the nursing 
newborn. For the same reason, drugs in breast 
milk are not an effective treatment for TB disease 
or LTBI in a nursing infant. Breastfeeding women 
taking INH should also take pyridoxine (vitamin 
B6) supplementation.
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